<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364837">
  <stage>Registered</stage>
  <submitdate>27/08/2013</submitdate>
  <approvaldate>2/09/2013</approvaldate>
  <actrnumber>ACTRN12613000973718</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of the Pharmacokinetics of IPX231 (L0007, C0001) in Healthy Subjects</studytitle>
    <scientifictitle>Evaluation of the Pharmacokinetics of IPX231 (L0007, C0001) in Healthy Subjects</scientifictitle>
    <utrn>U1111-1147-2306</utrn>
    <trialacronym>None</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Parkinson's disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Parkinson's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>IPX231 will be administered a single-center, open-label, randomized, single-dose, 4 sequence, 4 treatment crossover study. Treatments will be separated by at least a 7-day washout period. Subjects will remain at the clinical facility for approximately 24 hours during each of the 4 treatment periods. 
Treatment A: IPX231-L0007 (solution) 0.25 mL administered sublingually via syringe.
Treatment B: IPX231-L0007 (solution) 0.25 mL administered sublingually via spray pump.
Treatment C: IPX231-C0001 (encapsulated powder) 34.2 mg administered sublingually by dispersion of powder. 
Treatment D: Apomine Injection (0.2 mL of 10 mg apomorphine HCl/mL), containing 2.0 mg apomorphine HCl (1.76 mg apomorphine), administered subcutaneously per package insert instructions </interventions>
    <comparator>A single dose of Apomine Injection (0.2 mL of 10 mg apomorphine HCl/mL) will be administered as one of the treatments in this open-label, randomized, single-dose, 4 sequence, 4 treatment crossover study. </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetics</outcome>
      <timepoint>During each treatment period, blood samples will be obtained within 1 hour predose, and at 5, 10, 20, 30, 40, 50 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events (AEs), three serial 12-lead electrocardiograms (ECG), telemetry, physical exams, clinical laboratory test data, vital signs, and concomitant medications will be collected and evaluated over the course of the study.

AEs associated with IPX231 are expected to be similar to Apomine which include nausea, vomiting, drowsiness, somnolence, muscle pain and feeling faint.

AEs associated with Motilium include dry mouth, headache, nervousness, diarrhoea, nausea, heart burn, constipation and appetite disorders.
</outcome>
      <timepoint>Throughout the course of the study.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy adult subjects between 18 years and 45 years of age inclusive at the time of informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Presence of a clinically significant disorder, as determined by the Investigator, involving bleeding or hematologic or cardiovascular system abnormalities, acute infections, respiratory, renal, gastrointestinal, immunologic, hepatic, reproductive, endocrine, or neurologic system(s); or psychiatric disease; or oral trauma or disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>20/11/2013</anticipatedstartdate>
    <actualstartdate>28/02/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>21/03/2014</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Impax Laboratories, Inc.</primarysponsorname>
    <primarysponsoraddress>30831 Huntwood Avenue,
Hayward, CA  94544</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Impax Laboratories, Inc.</fundingname>
      <fundingaddress>30831 Huntwood Avenue,
Hayward, CA  94544</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To compare the pharmacokinetics of three IPX231  formulations administered subcutaneously as well as a single IPX231 formulation (IPX231-L0007) administered sublingually by two different methods: instillation via syringe versus spray in healthy adults.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Ethics Committee</ethicname>
      <ethicaddress>The Royal Prince Alfred Hospital
55 Commercial Rd.
Melbourne, Victoria 3004

</ethicaddress>
      <ethicapprovaldate>18/02/2014</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>23/01/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jason Lickliter</name>
      <address>Nucleus Network
89 Commercial Road
The Center for Commercial Studies
Melbourne, VIC  3000</address>
      <phone>+61 03 9076 8906</phone>
      <fax />
      <email>j.lickliter@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Emily Bingle</name>
      <address>Nucleus Network
89 Commercial Road
The Center for Commercial Studies
Melbourne, VIC  3000</address>
      <phone>+61 03 9076 3619</phone>
      <fax />
      <email>e.bingle@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jason Lickliter</name>
      <address>Nucleus Network
89 Commercial Road
The Center for Commercial Studies
Melbourne, VIC  3000</address>
      <phone>+61 03 9076 8906</phone>
      <fax />
      <email>j.lickliter@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>